Latest Conference Articles

Sotagliflozin Findings Suggest Benefit for Hard-to-Treat HF Population

Sotagliflozin Findings Suggest Benefit for Hard-to-Treat HF Population

November 17th 2020, 2:15am

American Heart Association Scientific Sessions

After recent setbacks, the beleaguered drug reduced cardiovascular events and may be a choice for patients with severe chronic kidney disease.

Fish Oil Debate Continues as Study Finds No Risk Reduction From Omega-3 Combo

Fish Oil Debate Continues as Study Finds No Risk Reduction From Omega-3 Combo

November 15th 2020, 3:58pm

American Heart Association Scientific Sessions

The investigator of the STRENGTH study says findings raise questions about the landmark REDUCE-IT trial, but other evidence suggests the drugs involved are different.

Four in Five HF Patients Could Benefit From Dapagliflozin, Registry Study Suggests

Four in Five HF Patients Could Benefit From Dapagliflozin, Registry Study Suggests

November 13th 2020, 8:47pm

American Heart Association Scientific Sessions

A registry study suggests 4 in 5 patients with heart failure might benefit from the SGLT2 inhibitor dapagliflozin.

Omecamtiv Mecarbil Shown to Improve Cardiac Function, Clinical Outcomes in GALACTIC-HF

Omecamtiv Mecarbil Shown to Improve Cardiac Function, Clinical Outcomes in GALACTIC-HF

November 13th 2020, 4:36pm

American Heart Association Scientific Sessions

Findings from the GALACTIC-HF trial presented at AHA Scientific Sessions 2020 showed that patients with heart failure (HF) with reduced ejection fraction who took omecamtiv mecarbil showed a significant 8% relative risk reduction in a composite of a HF event or death from cardiovascular causes, compared with those taking placebo.

Bringing Value-Based Insurance Design to Oncology: The New “Skin in the Game”

Bringing Value-Based Insurance Design to Oncology: The New “Skin in the Game”

October 29th 2020, 4:00am

Community Oncology Alliance

Value-based insurance design has made gains in oncology, but there's more work to do.

When Payers’ “Cost-Saving” Steps Don’t Help Patients

When Payers’ “Cost-Saving” Steps Don’t Help Patients

October 29th 2020, 4:00am

Community Oncology Alliance

Panelists at the Community Oncology Alliance Payer Exchange Summit take issue with strategies they say harm patients and don't save money in the long run.

Dr Bhuvana Sagar Discusses Payment Reform in Oncology

Dr Bhuvana Sagar Discusses Payment Reform in Oncology

October 28th 2020, 10:00pm

Community Oncology Alliance

Bhuvana Sagar, MD, national medical executive, Cigna Health Care, offers insights on implementing payment reform models in oncology after a session at the 2020 Community Oncology Alliance Payer Exchange Summit.

Dr Lalan Wilfong Talks Employer Involvement in Cancer Care Benefits

Dr Lalan Wilfong Talks Employer Involvement in Cancer Care Benefits

October 28th 2020, 9:45pm

Community Oncology Alliance

Lalan Wilfong, MD, executive vice president for quality programs and value-based care at Texas Oncology and Community Oncology Alliance payment reform co-chair, discusses the role of employers in cancer care benefits and issues stemming from the pandemic.

Defining Quality, Value in Cancer Care: What Employers Should Seek From Providers

Defining Quality, Value in Cancer Care: What Employers Should Seek From Providers

October 28th 2020, 5:27pm

Community Oncology Alliance

A panel of key opinion leaders discuss how employers and self-funded companies should assess provider quality and value in cancer care at the 2020 Community Oncology Alliance Virtual Payer Exchange Summit.

A Closer Look at 3 Oncology Payment Reform Projects

A Closer Look at 3 Oncology Payment Reform Projects

October 28th 2020, 12:44pm

Community Oncology Alliance

Evolution and collaboration are the fundamentals of bringing oncology payment reform plans to fruition, say 3 professionals on the front lines.